• Mayne Pharma and Mithra announce US launch of HALOETTE®, a generic version of NUVARING®

    Friday January 13th 2023

  • FINTEPLA®▼ (fenfluramine) oral solution recommended for approval in the EU for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)

    Monday December 19th 2022

  • New Idylla™ EGFR study shows reduction of time-to-treatment by 48% for lung cancer patients

    Tuesday November 8th 2022

  • Biocartis initiates commercialization in Europe of HepatoPredict (CE-IVD) test for liver cancer patients

    Monday October 10th 2022

  • IBA and SCK CEN launch Pantera, a joint-venture to produce actinium-225

    Thursday September 22nd 2022

  • New three-year BIMZELX®▼ (bimekizumab) data reinforce long-term maintenance of complete skin clearance in moderate to severe plaque psoriasis

    Wednesday September 7th 2022

  • Biocartis initiates commercialization in Europe of SkylineDx’s innovative Merlin™ Assay (CE-IVD) for melanoma patients

    Thursday September 1st 2022

  • argenx announces European Commission approval of VYVGART™ (efgartigimod alfa-fcab) for the treatment of generalized myasthenia gravis

    Thursday August 11th 2022

  • Your news here?

  • ANeuroTech receives positive feedback from the FDA for its pivotal Phase IIIb development programme for ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder

    Tuesday July 5th 2022

  • New agreement paves way for development of first African-owned COVID-19 vaccine

    Tuesday June 21st 2022

  • argenx announces the UK MHRA has granted early access to efgartigimod for generalized myasthenia gravis

    Tuesday May 31st 2022


Strategic Partners